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Background: Hypothermia has been used in cardiac surgery for many years for neuroprotection. Mild hypothermia
(MH) [body temperature (BT) kept at 32–35°C] has been shown to reduce both mortality and poor neurological
outcome in patients after cardiopulmonary resuscitation (CPR). This study investigated whether patients who were
expected to benefit neurologically from therapeutic hypothermia (TH) also had improved cardiac function.
Methods: The study included 30 patients who developed in-hospital cardiac arrest between September 17, 2012,
and September 20, 2013, and had return of spontaneous circulation (ROSC) following successful CPR. Patient BTs
were cooled to 33°C using intravascular heat change. Basal BT, systolic artery pressure (SAP), diastolic artery pressure
(DAP), mean arterial pressure (MAP), heart rate, central venous pressure, cardiac output (CO), cardiac index (CI),
global end-diastolic volume index (GEDI), extravascular lung water index (ELWI), and systemic vascular resistance
index (SVRI) were measured at 36°C, 35°C, 34°C and 33°C during cooling. BT was held at 33°C for 24 hours prior
to rewarming. Rewarming was conducted 0.25°C/h. During rewarming, measurements were repeated at 33°C,
34°C, 35°C and 36°C. A final measurement was performed once patients spontaneously returned to basal BT.
We compared cooling and rewarming cardiac measurements at the same BTs.
Results: SAP values during rewarming (34°C, 35°C and 36°C) were lower than during cooling (P < 0.05). DAP values
during rewarming (basal temperature, 34°C, 35°C and 36°C) were lower than during cooling. MAP values during
rewarming (34°C, 35°C and 36°C) were lower than during cooling (P < 0.05). CO and CI values were higher during
rewarming than during cooling. GEDI and ELWI did not differ during cooling and rewarming. SVRI values during
rewarming (34°C, 35°C, 36°C and basal temperature) were lower than during cooling (P < 0.05).
Conclusions: To our knowledge, this is the first study comparing cardiac function at the same BTs during cooling
and rewarming. In patients experiencing ROSC following CPR, TH may improve cardiac function and promote
favorable neurological outcomes.
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Figure 1 Flow diagram of the study.
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Hypothermia has been used in cardiac surgery for many
years for neuroprotection [1,2]. Mild hypothermia (body
temperature (BT) maintained at 32–35°C) has been
shown to reduce mortality and improve neurological
status by 24–30% in patients who have undergone car-
diopulmonary resuscitation (CPR) [3]. Although severe
hypothermia (BT <31°C) damages cardiac function, mild
hypothermia produces a cardioprotective effect [4,5].
Post-cardiac arrest brain injury results from global brain
ischemia during the reduction in general blood flow [6],
and prolonged cardiovascular collapse negatively impacts
neurologic outcome [7]. Therapeutic hypothermia (TH) is
the process whereby BT is reduced to a target temperature
of 32–34°C and maintained at this temperature for 24–48
hours following cardiac arrest (CA) and return of spon-
taneous circulation (ROSC) [8-11]. The 2010 International
Consensus on CPR and Emergency Cardiovascular
Care Science treatment recommendations [12], the 2010
American Heart Association CPR guidelines [13], the
2010 Japan Resuscitation Council Guidelines [14], and
the 2010 European Resuscitation Council (ERC) Guide-
lines [15] recommend TH following ROSC regardless of
cardiac rhythm.
The aim of this study was to determine whether
patients who were likely to benefit neurologically from
TH would also experience favorable effects on cardiac
function. Thus, we measured cardiac function during
cooling and rewarming periods in patients receiving TH
after CPR.
Methods
Patients were eligible if they developed CA in our hospital
and acquired ROSC following successful CPR between
September 17, 2012, and September 20, 2013 (Figure 1).
Patients were excluded if they: developed CA outside
the hospital; were < 15 years old; had late stage cancer;
demonstrated severe cardiogenic shock; were pregnant;
had cerebrovascular disease; demonstrated severe heart
disease or pulmonary artery thromboembolism; or had
aortic dissection or aneurysm.
Participants were admitted to the intensive care unit
and received care consistent with 2010 ERC guidelines
[15]. For internal BT measurements, a 16 F caliber, 44 cm
heat probe silicone urinary catheter (Rusch® sensor series
400, Teleflex Medical IDA Business and Technology Park,
Athlone, Ireland) was inserted. A 7 F three lumen central
venous catheter (GE-CVC3720Y, GEMED®, Istanbul,
Turkey) was placed in the right subclavian vein. A 9.3 F
caliber, five-lumen intravascular heat change catheter
(IC-3893 AE, ICY Intravascular Heat Exchange Catheter
Kit®, ZOLL Circulation Inc., Sunnyvale, CA, USA) was
placed into the right femoral vein. A 4 F caliber, 16 cm
Philips Continuous Cardiac Output arterial thermodilutioncatheter (PiCCO Plus®, Pulsion Medical Systems AG,
Munich, Germany) was placed in the right femoral artery
and connected to the monitor.
Patients were sedated with midazolam 0.02 mg/kg/h
and remifentanil 60 μg/kg/h intravenous infusions ac-
cording to the Ramsay Sedation Scale level 3–4 [16].
Sedation was continued throughout TH and rewarming.
During cooling, patients who demonstrated shaking that
could adversely affect hemodynamic balance received
0.03–0.05 mg/kg vecuronium intravenously. Consistent
with hospital protocol, patients whose mean arterial
pressure (MAP) was less than 60 mmHg and unresponsive
to a volume challenge received intravenous dopamine and
noradrenalin infusion.
Patient BTs were cooled to 33°C using intravascular heat
change at a rate of 0.5°C/h (Thermogard XP®, Alsius Corp.,
Chelmsford, MA, USA). Basal BT, systolic artery pressure
(SAP), diastolic artery pressure (DAP), MAP, heart rate
(HR), central venous pressure (CVP), cardiac output
(CO), cardiac index (CI), global end-diastolic volume
index (GEDI), extravascular lung water index (ELWI) and
systemic vascular resistance index (SVRI) values were
measured at 36°C, 35°C, 34°C and 33°C during cooling.
During the measurements, 15 mL of 0.9% saline solu-
tion at a temperature of less than 8°C was administered
through a central venous catheter over 10 seconds or less.
Table 1 Summary of demographic and clinical
characteristics of the 30 patients with cardiac arrest
Age in years (mean ± SD) 49.07 ± 18.04
Males 17 (56.7%)
Height (cm) 171.4 ± 6.9






Ventricular tachycardia 7 (23.3%)
Ventricular fibrillation 18 (60%)
Asystole 5 (16.7%)
CPR duration (min) 20 ± 9.4
Coronary angiography Yes 9 (30.0%)
None 21 (70.0%)
Time from ROSC to start of TH induction (min) 46.86 ± 14.73
SOFA Scores 11.93 ± 1.23
APACHE II Scores 22.77 ± 4.45
GCS: Glasgow Coma Scale.
CPR: Cardiopulmonary Resusication.
ROSC: Return of Spontaneous Circulation.
TH: Therapeutic Hypothermia.
SOFA: Sepsis-related Organ Failure Assessment.
APACHE: Acute Physiology and Chronic Health Evaluation.
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tion curves using the PiCCO® plus device. To ensure reli-
ability, three injections and three series of measurements
were performed for each temperature point, and mean
values were used for analysis. Incompatible values among
injections were deleted and the measurements were
repeated. Central catheters were recessed during mea-
surements. BT was held at 33°C for 24 hours prior to
rewarming. Rewarming was conducted at 0.25°C/h. Dur-
ing rewarming, measurements were repeated at 33°C,
34°C, 35°C and 36°C. A final measurement was performed
when patients spontaneously returned to basal BT.
We compared cooling and rewarming cardiac measure-
ments conducted at the same BTs using means, standard
deviations, ranges, medians, ratios and frequencies. Vari-
able distribution was controlled using the Kolmogorov
Smirnov test. Repeated measurements were analyzed with
paired sample t-tests. SPSS 21.0 software (IBM® Corp.,
Armonk, NY, USA) was used to analyze the data.
Permission to conduct this study was obtained from the
Clinical Studies Local Ethics Committee of the Republic
of Turkey Ministry of Health, Bagcilar Training and
Research Hospital (17.09.2012-76). Written informed
consent was obtained from the patients’ first degree
relatives.
Results
Patient demographic characteristics are presented in
Table 1. Cardiac measurements during cooling and
rewarming are shown in Table 2. SAP measurements
during rewarming at 34°C and 35°C were lower than
during rewarming at 33°C (P < 0.05). DAP values did not
differ during cooling or rewarming. MAP values during
rewarming at 34°C, 35°C and 36°C were lower than at
33°C (P < 0.05). HR values during cooling at 35°C, 34°C
and 33°C were lower than at basal temperature (P < 0.05).
HR values during rewarming at 34°C, 35°C, 36°C and basal
temperature were higher than at 33°C (P < 0.05). CVP
values during rewarming at 35°C and 36°C were lower
than at 33°C (P < 0.05). CO values during cooling at 35°C
and 33°C were lower than at basal temperature (P < 0.05).
CO values during rewarming to basal temperature
were higher than at 33°C (P < 0.05). CI values during
cooling at 36°C, 35°C and 33°C were lower than at basal
temperature (P < 0.05). CI values during rewarming to basal
temperature were higher than at 33°C (P < 0.05). GEDI
values during cooling at 36°C were lower than at basal
temperature. GEDI values at 33°C were higher than at basal
temperature (P < 0.05). GEDI values during rewarming
at 35°C and basal temperature were higher than at 33°C
(P < 0.05). ELWI values during cooling at 36°C and 35°C
were higher than at basal temperature (P < 0.05). SVRI
values during cooling at 35°C and 34°C were higher than
at basal temperature (P < 0.05). SVRI values duringrewarming at 34°C, 35°C, 36°C and at basal temperature
were higher than at 33°C (P < 0.05).
Some cardiac function values differed when measured at
the same temperature during cooling and rewarming
phases. SAP values at 34°C, 35°C and 36°C were lower
during rewarming compared with cooling (P < 0.05). DAP
values at basal temperature, 34°C, 35°C and 36°C were
lower during rewarming than during cooling. MAP values
at 34°C, 35°C and 36°C were lower during rewarming than
during cooling (P < 0.05). HR, CVP, GEDI and ELWI
values at the same BT did not differ between cooling
and rewarming periods. CO values were higher during
rewarming than during cooling (P < 0.05). CI values were
higher during rewarming than during cooling (P < 0.05).
SVRI values at 34°C, 35°C, 36°C and basal temperature
were lower during rewarming than during cooling (P <
0.05) (Table 2).
Discussion
In our comparison of cardiac function during the cooling
and rewarming following CA and ROSC, we found that
the greatest improvement occurred at 33°C at the begin-
ning of the rewarming period and that improvement in
cardiac function continued throughout the rewarming
period. This was consistent with a recent study showing
Table 2 Variation for the cardiac thermodilution maesurements at the same body temperature during cooling and
rewarming periods
Cooling (C)/Rewarming (RW) periods Mean. ± s.d. p Mean. ± s.d. p
BTbasal-C/BTbasal-RW SAP 10,7 ± 33,8 0,094 SVRI 792 ± 672 0,000
BT36-C/BT36-RW 12,9 ± 29,5 0,024 1089 ± 1791 0,002
BT35-C/BT35-RW 14,8 ± 29,1 0,009 1178 ± 1444 0,000
BT34-C/BT34-RW 11,9 ± 29,9 0,038 777 ± 1094 0,001
BT33-C/BT33-RW −6,7 ± 30,7 0,242 72 ± 1325 0,768
BTbasal-C/BTbasal-RW DAP 8,2 ± 19,7 0,030 CO −1,1 ± 1,6 0,001
BT36-C/BT36-RW 10,7 ± 18,3 0,003 −0,8 ± 1,6 0,009
BT35-C/BT35-RW 11,0 ± 19,6 0,005 −1,1 ± 1,6 0,000
BT34-C/BT34-RW 8,1 ± 15,7 0,008 −0,8 ± 1,4 0,003
BT33-C/BT33-RW 2,2 ± 19,2 0,529 −1,0 ± 1,5 0,002
BTbasal-C/BTbasal-RW MAP 6,7 ± 24,4 0,141 CI −0,6 ± 1,0 0,002
BT36-C/BT36-RW 11,8 ± 19,9 0,003 −0,5 ± 0,8 0,001
BT35-C/BT35-RW 12,0 ± 19,8 0,002 −0,7 ± 0,9 0,000
BT34-C/BT34-RW 9,1 ± 19,7 0,017 −0,5 ± 0,8 0,002
BT33-C/BT33-RW −2,3 ± 24,2 0,602 −0,5 ± 0,9 0,012
BTbasal-C/BTbasal-RW HR 4,1 ± 19,9 0,273 GEDI 22,0 ± 140,2 0,397
BT36-C/BT36-RW 3,8 ± 24,2 0,397 −72,3 ± 167,1 0,025
BT35-C/BT35-RW −3,4 ± 18,5 0,326 −83,8 ± 285,3 0,118
BT34-C/BT34-RW −2,7 ± 16,5 0,384 −18,6 ± 171,8 0,557
BT33-C/BT33-RW 2,7 ± 19,5 0,450 −0,9 ± 117,5 0,966
BTbasal-C/BTbasal-RW CVP 0,8 ± 7,2 0,562 ELWI 0,1 ± 2,9 0,902
BT36-C/BT36-RW 1,8 ± 5,4 0,074 1,3 ± 4,1 0,083
BT35-C/BT35-RW 1,8 ± 5,3 0,081 1,0 ± 3,8 0,148
BT34-C/BT34-RW 1,9 ± 5,6 0,078 0,6 ± 3,6 0,394
BT33-C/BT33-RW 1,7 ± 5,6 0,111 0,7 ± 2,8 0,206
Paired sample t test.
SAP measurements did not demonstrate any difference at Tbasal-C/Tbasal-RW and 33°C (p > 0.05). SAP values during rewarming at 34°C, 35°C, 36°C were lower as
compared to measurements in cooling period (p < 0.05). DAP measurements did not demonstrate any difference at 33°C (p > 0.05). DAP values during rewarming at
Tbasal-RW, 34°C, 35°C, 36°C were lower as compared to the measurements during cooling period. MAP meaurements did not demonstrate any difference at Tbasal-C/
Tbasal-RW and 33°C (p < 0.05). MAP values during rewarming at 34°C, 35°C, 36°C were lower as compared to measurements during cooling period (p < 0.05). HR and
CVP measurement values at the same body temperature during rewarming and cooling period did nor demonstrate any difference (p > 0.05). COmeasurements were
higher during the rewarming period (p < 0.05). CImeasurements were higher during the rewarming period (p < 0.05). GEDI and ELWI measurements during rewarming
and cooling periods did not demonstrate any difference at the same body temperatures (p > 0.05). SVRI measurements during rewarming and cooling periods at 33°C
did nor demonstrate any difference (p > 0.05). SVRI values during rewarming period at 34°C, 35°C, 36°C and Tbasal-RW period were lower (p < 0.05).
C: Cooling, RW: Rewarning, BT: Body temperature, SAP: Systolic arterial pressure, DAP: Diastolic arterial pressure, MAP: Mean arterial pressure, HR: Heart rate, CVP:
Central venous pressure, SVRI: Systemic vascular resistance index, CO: Cardiac output, CI: Cardiac index, GEDI: Global end-diastolic volume index, ELWI: Extravascular lung
water index.
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enced improved cardiac function during rewarming.
The rationale for applying TH in patients experiencing
ROSC after CPR is to improve brain tolerance to ischemia.
There are increasing reports of neurological disease-free
survival and recovery in these situations [17,18]. Experi-
mental studies demonstrated that hypothermic blood
introduced to the coronary sinus during heart ischemia
minimizes reperfusion damage and infarct area [19]. TH
also protects contractility, prevents microvascular ob-
structions, and reduces left ventricular remodeling [20].
In addition, the reduced metabolic rate, decreased tissueapoptosis, and heat shock protein induction offer cellular
protective effects [21]. The cardioprotective effects of TH
are directly related to timing. Late induction or a slow
cooling speed does not improve cardiac function [22,23].
The time from ROSC to TH induction was about 45 mi-
nutes in our study. Although we selected 0.5°C/h for cool-
ing, new studies suggest that faster cooling (>0.5°C/h) to
the targeted BT is associated with better cardioprotection
[24,25]. According to Nagao et al., TH is more effective
if begun during CPR prior to ROSC, and early cooling
during CA is neuroprotective and myocardioprotective
[26]. TH during CPR also increases resuscitation rates,
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decreases the myocardial infarct area [27,28].
Schmidt-Schweda et al. showed that HR decreased
whereas stroke volume (SV), CI and CO increased in
cardiomyopathic patients receiving short-term cooling
[29]. However, these improvements were lost during
rewarming, and the authors interpreted TH application
as having a positive inotropic effect [29]. In contrast, CO
and CI in our study improved at the end of the cooling
period and throughout rewarming, with the highest
levels occurring at the end of the process. As per our
protocol, dopamine and noradrenalin infusions were
decreased or eliminated during rewarming. There were
significant increases in CO and CI, and a significant
decrease in SVRI, but no significant change in GEDI or
HR during the rewarming period compared with the cool-
ing period. This might imply that there was an increased
SV during the rewarming period resulting from either
increased contractility or decreased afterload or both.
Unfortunately, recent study findings could not distin-
guished between the two possibilities. Gibson et al.
suggested that the TH adverse effects of bradycardia and
hypotension actually benefit patients, similar to the effect
of beta-blockers [30]. When Riaz et al. reported results of
cooling patients to 32°C to 34°C for 24 hours following
ventricular tachycardia or ventricular fibrillation, they
emphasized the risk of QT interval prolongation, particu-
larly in those who had received amiodarone [31].
Management of patients receiving CPR during TH
is difficult [8,9]. The most frequent cause of complex
hemodynamic instability is arterial hypotension, which
is characterized by hypovolemia, reversible myocardial
stunning and excessive vasodilation [32-36]. Pulmonary
dysfunction is related to cardiogenic pulmonary edema
caused by left ventricular dysfunction and non-cardiogenic
edema caused by inflammatory, infective and physical
damage [9]. We used PiCCO® monitoring to improve pa-
tient care and track cardiac function during this difficult
post-ROSC period. It has been reported that PiCCO®
monitoring with transpulmonary thermodilution may be
compromised in patients receiving TH [37,38]. For this
reason, we compared cardiac function measurements at
the same BTs during cooling and rewarming. However,
there are inadequate prospective studies published regard-
ing the reliability of PiCCO® measurements at low BTs.
Further prospective studies similar to ours are needed.
Fluid and electrolyte balance during TH is an important
challenge [39]. Cooling can cause peripheral vasoconstric-
tion, reduce vascular volume and CVP, and the patient
seems relatively hypovolemic [40]. In our study, we
detected no significant change in CVP and HR, but we
did detect higher CO and CI values. During these thera-
peutic cooling and rewarming periods, patient fluid status
must be monitored closely to maintain volume balance,and a vasopressor added when necessary to maintain
adequate blood pressure.
Post-resuscitation hemodynamic instability is charac-
terized by a low CI and normal or low filling pressures
[33]. The CI rapidly increases 24 hour after CA, inde-
pendent of filling pressures and vasoactive agents [41].
Recovery of this myocardial dysfunction is most often
obtained within 24–48 hours and this condition might
have played a role in our findings [33]. Full recovery
with discontinuation of inotropic support has usually
occurred by 72 hours after ROSC [41]. In contrast, TH
has been shown to produce negative effects as well as
cardioprotective effects. Espinoza et al. showed that TH
in pigs decreased SV, ejection fraction and strain in
hearts paced at 33°C, and concluded that TH may lead
to systolic and diastolic dysfunction [42]. When Bassin
et al. induced hypothermia in sheep using venous extra-
corporeal circulation, they observed increased hetero-
geneity in hypothermic depolarization and repolarization
during cardiac rhythm tracking by 12-derivation ECG,
thus providing strong evidence that hypothermia to 34°C
produced adverse effects [43].
Several limitations of the current study deserve men-
tion. We did not select a control group so we do not know
how cardiac functions would have differed from patients
who did not receive TH. We were also unable to study
patients undergoing angioplasty following CA as a result
of myocardial infarction or patients with known under-
lying cardiac disease. Once TH was complete, we did not
collect PiCCO® measurements. Thus, we could not deter-
mine whether the beneficial cardiac function changes
persisted over time.
Conclusions
This study found that CO and CI increased together
during rewarming following TH. The lack of difference in
HR measurements indicate that CO and CI increased by
increases in TH and SV. To our knowledge, this is the first
study comparing cardiac function at the same BTs during
cooling and rewarming. In patients experiencing ROSC
following CPR, TH may improve cardiac function. Further
studies are needed to confirm these results and the rela-
tionship between TH and post-resuscitation myocardial
function in patients with different neurological status.
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